These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17331066)

  • 1. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease.
    Baranova A; Randhawa M; Jarrar M; Younossi ZM
    Expert Rev Mol Diagn; 2007 Mar; 7(2):195-205. PubMed ID: 17331066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of fibrosis in nonalcoholic fatty liver disease.
    Hoteit MA; Anania FA
    Curr Gastroenterol Rep; 2007 Mar; 9(1):47-53. PubMed ID: 17335677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
    Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
    Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).
    Liu Q; Bengmark S; Qu S
    Lipids Health Dis; 2010 Apr; 9():42. PubMed ID: 20426802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease.
    Wang Z; Yao T; Pini M; Zhou Z; Fantuzzi G; Song Z
    Am J Physiol Gastrointest Liver Physiol; 2010 May; 298(5):G634-42. PubMed ID: 20203061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects.
    Ercin CN; Dogru T; Tasci I; Erdem G; Sonmez A
    Obes Surg; 2008 Oct; 18(10):1357; author reply 1358. PubMed ID: 18563498
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of inflammation in nonalcoholic steatohepatitis.
    Choi S; Diehl AM
    Curr Opin Gastroenterol; 2005 Nov; 21(6):702-7. PubMed ID: 16220049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.
    Qureshi K; Abrams GA
    World J Gastroenterol; 2007 Jul; 13(26):3540-53. PubMed ID: 17659704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
    Rector RS; Thyfault JP; Wei Y; Ibdah JA
    World J Gastroenterol; 2008 Jan; 14(2):185-92. PubMed ID: 18186553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Adipose Tissue-Derived miRNAs in Metabolic Syndrome, Obesity, and Cancer.
    Heyn GS; Corrêa LH; Magalhães KG
    Front Endocrinol (Lausanne); 2020; 11():563816. PubMed ID: 33123088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adipokines as novel biomarkers and regulators of the metabolic syndrome.
    Deng Y; Scherer PE
    Ann N Y Acad Sci; 2010 Nov; 1212():E1-E19. PubMed ID: 21276002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adipokine genetics: unbalanced protein secretion by human adipose tissue as a cause of the metabolic syndrome].
    Baranova AV
    Genetika; 2008 Oct; 44(10):1338-55. PubMed ID: 19062531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipose-Derived Lipid-Binding Proteins: The Good, the Bad and the Metabolic Diseases.
    Frances L; Tavernier G; Viguerie N
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease.
    Coronel-Castillo CE; Qi X; Contreras-Carmona J; Ramírez-Pérez OL; Méndez-Sánchez N
    Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):531-540. PubMed ID: 30905208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer.
    Rajesh Y; Sarkar D
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipokines in liver diseases.
    Marra F; Bertolani C
    Hepatology; 2009 Sep; 50(3):957-69. PubMed ID: 19585655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice.
    Prakash S; Rai U; Kosuru R; Tiwari V; Singh S
    Biochimie; 2020 Jan; 168():198-209. PubMed ID: 31715215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.